Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD of LIGAND PHARMACEUTICALS INC from 2019 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Ligand Pharmaceuticals Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and change rate from 2019 to Q3 2025.
- Ligand Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was $141M.
- Ligand Pharmaceuticals Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2025 was $63M, a 7.08% increase year-over-year.
- Ligand Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $2.52M, a 96% decline from 2023.
- Ligand Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $63.7M, a 76.8% increase from 2022.
- Ligand Pharmaceuticals Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $36M, a 50.1% decline from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)